Clinical Trial Update: Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study

View source ↗

Summary

PALMARES-2 is a multicenter Italian study evaluating the ability to predict outcomes for patients with advanced HR-positive, HER2-negative breast cancer treated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Drugs mentioned

• Abemaciclib (abemaciclib)
• Palbociclib (palbociclib)
• Ribociclib (ribociclib)

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Breast Adenocarcinoma, Breast Cancer Stage IV | Status: RECRUITING